Reverse DCF
What growth does the market imply for AARTIDRUGS?
Working backwards from the current price to find the FCF growth assumption baked in.
very aggressive
22.2% implied annual FCF growth
The market is pricing in exceptional growth that only a handful of companies sustain for a decade. For context, this company has historically grown at -4.0%. High execution risk.
Current Price
₹372
Historical Growth
-4.0%
FCF Yield
1.99%
Price / FCF
50.4x
Plain English
To justify today's price of $371.95, AARTIDRUGS.NS needs to grow its free cash flow at 22.2% per year for the next 10 years. That is 26.2% faster than its historical growth rate of -4.0%. At its historical growth rate, the stock cannot justify its current price within a 20-year horizon. The market is pricing in a step-change in performance.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Historical | -4.0% | ₹0 | -100.0% |
| GDP rate | 10.0% | ₹105 | -71.8% |
| Half implied | 11.1% | ₹120 | -67.7% |
| Implied | 22.2% | ₹371 | -0.2% |
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, Monte Carlo, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.